المؤلفون: Wen-He Pan, Bing-Qing Liang, Quan Zhou, Ling-jing Yuan, Guo-Xin Hu, Tian Lan, Xiao-Xia Hu

المصدر: European Journal of Drug Metabolism and Pharmacokinetics. 42:261-268

مصطلحات موضوعية: Male, Metabolite, Pharmacology, Atomoxetine Hydrochloride, 030226 pharmacology & pharmacy, Rats, Sprague-Dawley, Inhibitory Concentration 50, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Phenols, Pharmacokinetics, In vivo, medicine, Animals, Humans, Drug Interactions, Pharmacology (medical), IC50, Flavonoids, Adrenergic Uptake Inhibitors, Dose-Response Relationship, Drug, Propylamines, Atomoxetine, Rats, chemistry, Area Under Curve, Microsomes, Liver, Microsome, Myricetin, 030217 neurology & neurosurgery, medicine.drug, Atomoxetine hydrochloride

الوصف: Atomoxetine is the first non-stimulant drug to be approved for the treatment of ADHD, while the effect of myricetin on the pharmacokinetic of atomoxetine in rats or human is still unknown. The present work was to study the impact of myricetin on the metabolism of atomoxetine both in vivo and in vitro. Twenty healthy male Sprague–Dawley rats were randomly divided into four groups: A (control group), B (100 mg/kg myricetin), C (50 mg/kg myricetin), and D (25 mg/kg myricetin). A single dose of atomoxetine (10 mg/kg) was administrated half an hour later. In addition, human and rat liver microsomes were performed to determine the effect of myricetin on the metabolism of atomoxetine in vitro. Group B, C, D all increased the C max and AUC of atomoxetine, but decreased the C max and AUC of 4-hydroxyatomoxetine. Moreover, myricetin showed inhibitory effect on human and rat microsomes, the IC50 of myricetin was 8.651 and 35.45 µmol/L, respectively. Our study showed that myricetin could significantly inhibit the formation of atomoxetine metabolite both in vivo and in vitro. It is recommended that the effect of myricetin on the metabolism of atomoxetine should be noted and atomoxetine plasma concentration should be monitored.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ecdaff41d3a0b8f11d4bb1d32d61e4Test
https://doi.org/10.1007/s13318-016-0347-0Test

المؤلفون: Huiying Qiu, Chongmei Huang, Xiaoqian Xu, Jianmin Yang, Xiong Ni, Shuqing Lü, Xiao-Xia Hu, Jianmin Wang

المصدر: International Journal of Hematology. 89:34-38

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Neutropenia, Gastroenterology, Dexamethasone, Bortezomib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Epirubicin, business.industry, Remission Induction, Hematology, Middle Aged, medicine.disease, Boronic Acids, Survival Analysis, Hematopoietic Stem Cell Mobilization, Thalidomide, Surgery, Regimen, Treatment Outcome, Pyrazines, Blood Component Removal, Female, Liver function, Multiple Myeloma, business, medicine.drug

الوصف: The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM). The BADT regimen consisted of a maximum of eight 4-week cycles of: intravenous bortezomib (1.0 mg/m(2)) and intravenous epirubicin (12 mg/m(2)) on days 1, 4, 8, and 11; dexamethasone (20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12; and oral thalidomide (100 mg/m(2)) on days 1-28. Twelve patients with MM were included in the study, of whom four had not been previously treated and eight had been previously treated with at least one cycle of a systemic combined regimen. All the patients completed at least two cycles of treatment, with an average of five cycles; the complete response (CR) rate was 83.3% (10/12) and stabilization of disease was 16.7% (2/12). The average number of cycles required to achieve CR was 1.9 (range 1-6). In three patients, mobilization of peripheral blood stem cells allowed a sufficient quantity of CD34+ cells to be harvested for future autotransplantation. The main adverse reactions included peripheral neuropathy (4/12), thrombocytopenia (3/12), electrocardiographic abnormalities (4/12), neutropenia (5/12), and liver function impairment (4/12), primarily grade I-II. Infection occurred in four patients with neutropenia, including one patient who developed sepsis. The estimated 1-year overall survival rate was 91.7 +/- 8.0%, and the estimated 1-year disease-free survival was 75.0 +/- 12.5%. BADT is a highly effective combined regimen, with acceptable toxicity, for the treatment of multiple myeloma.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5e32fe3e43833bf167e0fb2bfd8566Test
https://doi.org/10.1007/s12185-008-0218-9Test